ADMA Biologics Inc (NASDAQ:ADMA) Director Steve Elms Sells 92,941 Shares

ADMA Biologics Inc (NASDAQ:ADMA) Director Steve Elms sold 92,941 shares of the firm’s stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $21.69, for a total value of $2,015,890.29. Following the completion of the transaction, the director now owns 2,031,730 shares of the company’s stock, valued at approximately $44,068,223.70. This represents a 4.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Steve Elms also recently made the following trade(s):

• On Monday, June 16th, Steve Elms sold 194,749 shares of ADMA Biologics stock. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76.
• On Friday, June 13th, Steve Elms sold 137,931 shares of ADMA Biologics stock. The shares were sold at an average price of $20.82, for a total transaction of $2,871,723.42.

ADMA Biologics Trading Down 7.4%

ADMA Biologics stock opened at $18.89 on Wednesday. The stock has a market cap of $4.51 billion, a PE ratio of 22.22 and a beta of 0.47. The stock has a 50-day moving average price of $20.98 and a 200 day moving average price of $18.83. ADMA Biologics Inc has a 52 week low of $10.21 and a 52 week high of $25.67. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to analysts’ expectations of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business’s quarterly revenue was up 40.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.08 earnings per share. Equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Institutional Trading of ADMA Biologics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Van ECK Associates Corp purchased a new stake in ADMA Biologics in the 4th quarter valued at about $3,424,000. New York State Teachers Retirement System grew its holdings in ADMA Biologics by 24.1% in the fourth quarter. New York State Teachers Retirement System now owns 113,090 shares of the biotechnology company’s stock valued at $1,939,000 after purchasing an additional 21,976 shares during the period. Rhumbline Advisers grew its holdings in ADMA Biologics by 1.0% in the fourth quarter. Rhumbline Advisers now owns 621,079 shares of the biotechnology company’s stock valued at $10,651,000 after purchasing an additional 5,881 shares during the period. Principal Financial Group Inc. grew its holdings in ADMA Biologics by 5.4% in the fourth quarter. Principal Financial Group Inc. now owns 1,259,014 shares of the biotechnology company’s stock valued at $21,592,000 after purchasing an additional 64,793 shares during the period. Finally, D.A. Davidson & CO. purchased a new stake in ADMA Biologics in the fourth quarter valued at approximately $202,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Raymond James Financial raised their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research note on Thursday, May 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. Finally, Wall Street Zen downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.25.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.